Companies · Biotechnology

Ovala, Inc.

PITTSBURGH · Biotechnology

Diligence memoA one-page analyst read on Ovala, Inc. — recommendation, valuation, rhythm, risks.
$7.1M
Total raised · real
2
Rounds
0.8×
Latest step-up
Top 51%
Sector rank · raised
Seed
Latest stage · inferred · Mon Mar 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Ovala, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.35× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
  • Within the normal band (135% of peer median) for its niche.
Active
  • Last raise 4 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Ovala, Inc. is one of 4291 Biotechnology companies tracked from PITTSBURGH. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2026-03-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2022-06-22 Raised $3.9M (real) Modeled valuation $57M (est)$3.9M$57MSeed2022Seed · 2026-03-16 Raised $3.3M (real) Modeled valuation $6.1M (est)$3.3M$6.1MSeed2026+$3.3MCumulative $7.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.9M · 2022
Seed extension$3.3M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$6.1M
Base estimate est.
$2.3M
Conservative case
$10.3M
Upside case
$16.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $57.4M · 2022-06-222022Seed · modeled $6.1M · 2026-03-162026
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
0.3 yr
Elapsed time used
0.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
45 mo
Avg between rounds
$1.9M/yr
Capital velocity
4.0 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$7.1M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.9× above median
This company$3.3M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$6.1M
Sector median$64.2M

Raised more than 50% of sector peers (real $). Modeled value above 13% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #38 of 99.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Carna Inc. · Seed Raised $3.4M · modeled $12.4M (est)NRX Pharmaceuticals, Inc. · Seed Raised $3.5M · modeled $12.3M (est)Vicora, Inc. · Seed Raised $3.4M · modeled $11.9M (est)MH3D, Inc. · Seed Raised $3.3M · modeled $11.9M (est)Oral Genome Corp. · Seed Raised $3.1M · modeled $11.2M (est)Synlico Inc. · Seed Raised $5.2M · modeled $10.1M (est)Auxilium Biotechnologies Inc. · Seed Raised $7.2M · modeled $9.7M (est)Silexion Therapeutics Corp · Seed Raised $3.6M · modeled $9.6M (est)Bodark Investment Group LP · Seed Raised $3.3M · modeled $9.4M (est)Sower Solas I Sidecar III, LLC · Seed Raised $3.5M · modeled $9.3M (est)Sift Biosciences, Inc. · Seed Raised $3.8M · modeled $8.4M (est)SiVEC Biotechnologies, Inc. · Seed Raised $3.3M · modeled $8.4M (est)Ovala, Inc. (this company) Raised $7.1M · modeled $6.1M (est)Ovala, Inc.
CompanyStageRaised · realValue · estvs peer med.
Carna Inc.Seed$3.4M$12.4M2.72×
NRX Pharmaceuticals, Inc.Seed$3.5M$12.3M2.70×
Vicora, Inc.Seed$3.4M$11.9M2.61×
MH3D, Inc.Seed$3.3M$11.9M2.61×
Oral Genome Corp.Seed$3.1M$11.2M2.45×
Synlico Inc.Seed$5.2M$10.1M2.22×
Auxilium Biotechnologies Inc.Seed$7.2M$9.7M2.13×
Silexion Therapeutics CorpSeed$3.6M$9.6M2.10×
Bodark Investment Group LPSeed$3.3M$9.4M2.06×
Sower Solas I Sidecar III, LLCSeed$3.5M$9.3M2.05×
Sift Biosciences, Inc.Seed$3.8M$8.4M1.85×
SiVEC Biotechnologies, Inc.Seed$3.3M$8.4M1.85×
Ovala, Inc. this companySeed$7.1M$6.1M1.35×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.9M2022-06-22$19.3M$57.4M90%
Seed$3.3M2026-03-16$16.3M$6.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.9M2022-06-22
    • First recorded raise — entered as Seed.
    • 9 investors on this round.
  2. Seed$3.3M2026-03-16
    • Raised again after 45 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 8 investors on this round.
Intelligence
2029 ~Q4
Modeled next raise · ~45mo cadence
$3.3M
Modeled next size est.range $3.3M$5.2M
0.8×
Last step-up
$1.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Richard Petersen4 other2026-03
Christopher Petersen3 other2026-03
Jeffrey Quillen2 other2026-03
Michael Tovian2 other2026-03
Stephen Bollinger2 other2022-06
Brad Richard Petersen1 other2022-06
Christopher Richard Petersen1 other2022-06
Michael Richard Tovian1 other2022-06
Brad Petersen2026-03
Jeffrey Richard Quillen2022-06
John Richard Sipple2022-06
John Sipple2026-03
Richard Richard Petersen2022-06
Registry & provenance

Ovala, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1936997
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rinovum Women's Health, LLCOther Health CareSeries A$20.7M$121.1Mnetwork5 shared operators
Intimate Bridge 2 Conception, Inc.Other Health CareSeries A$10.6M$100.9Mnetwork4 shared operators
Neograft Technologies, Inc.Software / TechSeries A$34.3M$138.7Mnetwork3 shared operators
inSoma Bio, Inc.BiotechnologySeed$6.9M$6.6Msame sector · same stage
Amplified Sciences, Inc.BiotechnologySeed$7.4M$7.8Msame sector · same stage
Tharimmune, Inc.BiotechnologySeed$6.6M$7.1Msame sector · same stage
Altis Biosystems, Inc.BiotechnologySeed$6.6M$6.8Msame sector · same stage
Apexian Pharmaceuticals, Inc.BiotechnologySeed$7.7M$6.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Pillar Biosciences, Inc.BiotechnologySeries B$715.6M85%
Biomatrica, Inc.BiotechnologySeries B$720.2M85%
Pepper Bio, Inc.BiotechnologySeed$1.7M85%
Apexigen, Inc.BiotechnologySeries C$85.5M84%
Apexian Pharmaceuticals, Inc.BiotechnologySeed$6.7M84%
StrideBio, Inc.BiotechnologySeries C$1.5B84%
Liquidia Technologies IncBiotechnologySeries B$890.0M84%
Paterna Biosciences, Inc.BiotechnologySeed$38.9M84%
Frequently asked
How much funding has Ovala, Inc. raised?
Ovala, Inc. has raised approximately $7.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Ovala, Inc.'s estimated valuation?
Provath's modeled valuation for Ovala, Inc. is approximately $6.1M (modeled range $2.3M–$10.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Ovala, Inc. at?
Ovala, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Mar 16.
What does Ovala, Inc. do and where is it based?
Ovala, Inc. operates in the Biotechnology sector, based in PITTSBURGH.
Explore related

See where Ovala, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ovala, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.